| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AT1 Overview
Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing in Australia and internationally.
Atomo Diagnostics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.36 |
| 52 Week High | AU$0.13 |
| 52 Week Low | AU$0.37 |
| Beta | 0 |
| 1 Month Change | 24.14% |
| 3 Month Change | 80.00% |
| 1 Year Change | 14.29% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.69% |
Recent News & Updates
We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)
Atomo Diagnostics Limited ( ASX:AT1 ) is possibly approaching a major achievement in its business, so we would like to...
Shareholder Returns
| AT1 | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.6% |
| 1Y | 14.3% | -7.6% | 21.3% |
Return vs Industry: AT1 exceeded the Australian Medical Equipment industry which returned -7.6% over the past year.
Return vs Market: AT1 underperformed the Australian Market which returned 21.3% over the past year.
Price Volatility
| AT1 volatility | |
|---|---|
| AT1 Beta | 0 |
| Industry Beta | 0.57 |
| Market Beta | 1 |
Stable Share Price: AT1 is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: AT1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | John Kelly | https://atomodiagnostics.com |
Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing in Australia and internationally. The company offers AtomoRapid RDT platforms to suit various blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases. Its rapid test devices are used by healthcare professionals and by consumers to screen for a range of diseases and medical conditions, including HIV infection.
Atomo Diagnostics Fundamentals Summary
| AT1 fundamental statistics | |
|---|---|
| Market Cap | AU$204.70m |
| Earnings (TTM) | -AU$6.02m |
| Revenue (TTM) | AU$6.72m |
30.5x
P/S Ratio-34.0x
P/E RatioIs AT1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AT1 income statement (TTM) | |
|---|---|
| Revenue | AU$6.72m |
| Cost of Revenue | AU$3.63m |
| Gross Profit | AU$3.09m |
| Expenses | AU$9.11m |
| Earnings | -AU$6.02m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 29, 2021
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 45.96% |
| Net Profit Margin | -89.66% |
| Debt/Equity Ratio | 0% |
How did AT1 perform over the long term?
See historical performance and comparisonValuation
Is Atomo Diagnostics undervalued compared to its fair value and its price relative to the market?
31.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AT1 (A$0.36) is trading below our estimate of fair value (A$0.53)
Significantly Below Fair Value: AT1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AT1 is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: AT1 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AT1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AT1 is overvalued based on its PB Ratio (6.8x) compared to the AU Medical Equipment industry average (4.5x).
Future Growth
How is Atomo Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
102.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AT1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: AT1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AT1's is expected to become profitable in the next 3 years.
Revenue vs Market: AT1's revenue (36% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: AT1's revenue (36% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AT1 is forecast to be unprofitable in 3 years.
Past Performance
How has Atomo Diagnostics performed over the past 5 years?
-14.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AT1 is currently unprofitable.
Growing Profit Margin: AT1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AT1 is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare AT1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AT1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: AT1 has a negative Return on Equity (-20.01%), as it is currently unprofitable.
Financial Health
How is Atomo Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: AT1's short term assets (A$25.5M) exceed its short term liabilities (A$2.1M).
Long Term Liabilities: AT1's short term assets (A$25.5M) exceed its long term liabilities (A$23.1K).
Debt to Equity History and Analysis
Debt Level: AT1 is debt free.
Reducing Debt: AT1 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AT1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AT1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Atomo Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AT1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AT1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AT1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AT1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AT1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average board tenure
CEO
John Kelly
no data
Tenure
AU$467,301
Compensation
Mr. John Michael Kelly founded Atomo Diagnostics Ltd. in 2010 and serves as its Chief Executive Officer & Managing Director. Mr. Kelly has significant med-tech experience, having held senior operational an...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD349.15K) is below average for companies of similar size in the Australian market ($USD552.62K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: AT1's board of directors are considered experienced (3.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Atomo Diagnostics Limited's employee growth, exchange listings and data sources
Key Information
- Name: Atomo Diagnostics Limited
- Ticker: AT1
- Exchange: ASX
- Founded: 2010
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$204.695m
- Shares outstanding: 568.60m
- Website: https://atomodiagnostics.com
Location
- Atomo Diagnostics Limited
- 701-703 Parramatta Road
- Level 2
- Leichhardt
- New South Wales
- 2040
- Australia
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/24 07:02 |
| End of Day Share Price | 2021/10/22 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.